DexCom, Inc. (DXCM) Stock
DXCM Key Statistics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
CEO: Jacob Steven Leach. Company website
DXCM — Frequently Asked Questions
What is the DXCM stock price today?
DexCom, Inc. (DXCM) trades at $80.35, up 0.53% on the day, as of Nov 12, 2026 09:30 UTC.
What is DexCom, Inc.'s market cap?
DexCom, Inc. has a market capitalisation of $29.96B, calculated from the live DXCM share price and shares outstanding.
What is the P/E ratio of DXCM?
DXCM trades at a trailing P/E of 31.63, from earnings per share of $2.54 over the last twelve months.
How much revenue does DexCom, Inc. make?
DexCom, Inc. generated revenue of $5.10B over the trailing twelve months, which puts the stock at 5.87 times sales.
What is the 52-week range for DXCM?
DXCM has traded between $54.11 and $92.59 over the past 52 weeks, and the last price is 13.2% below that high.
Is DexCom, Inc. profitable?
Yes. DexCom, Inc. keeps 19.41% of revenue as net income over the trailing twelve months.
What is the analyst price target for DXCM?
Wall Street analysts rate DXCM Buy, with an average price target of $97.85, 21.8% above the current price.
What sector is DexCom, Inc. in?
DexCom, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of DexCom, Inc.?
Jacob Steven Leach is the chief executive of DexCom, Inc., which employs 11,050 people.
Where can I track DXCM in real time?
QFI Terminal shows DXCM with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See DXCM live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open DXCM in Terminal See plans